Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Highly efficient therapeutic gene editing of human hematopoietic stem cells

Open access

Abstract

Re-expression of the paralogous γ-globin genes (HBG1/2) could be a universal strategy to ameliorate the severe β-globin disorders sickle cell disease (SCD) and β-thalassemia by induction of fetal hemoglobin (HbF, α2γ2)1. Previously, we and others have shown that core sequences at the BCL11A erythroid enhancer are required for repression of HbF in adult-stage erythroid cells but are dispensable in non-erythroid cells2–6. CRISPR–Cas9-mediated gene modification has demonstrated variable efficiency, specificity, and persistence in hematopoietic stem cells (HSCs). Here, we demonstrate that Cas9:sgRNA ribonucleoprotein (RNP)-mediated cleavage within a GATA1 binding site at the +58 BCL11A erythroid enhancer results in highly penetrant disruption of this motif, reduction of BCL11A expression, and induction of fetal γ-globin. We optimize conditions for selection-free on-target editing in patient-derived HSCs as a nearly complete reaction lacking detectable genotoxicity or deleterious impact on stem cell function. HSCs preferentially undergo non-homologous compared with microhomology-mediated end joining repair. Erythroid progeny of edited engrafting SCD HSCs express therapeutic levels of HbF and resist sickling, while those from patients with β-thalassemia show restored globin chain balance. Non-homologous end joining repair-based BCL11A enhancer editing approaching complete allelic disruption in HSCs is a practicable therapeutic strategy to produce durable HbF induction. Optimized co…

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0401-y

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
From the PDF
Image 2
From the PDF
Extended Data Figure 3 |. Long-term multi-lineage engraftment of BCL11A enhancer edited HSPCs in immunodeficient mice.
Extended Data Figure 3 |. Long-term multi-lineage engraftment of BCL11A enhancer edited HSPCs in immunodeficient mice.From the PDF
Image 4
From the PDF
Extended Data Figure 5 |. Long-term multi-lineage reconstituting HSCs edited with 3xNLSCas9.
Extended Data Figure 5 |. Long-term multi-lineage reconstituting HSCs edited with 3xNLSCas9.From the PDF
Extended Data Figure 6 |. Off-target analysis of human CD34 + HSPCs edited by SpCas9 RNP targeting BCL11A enhancer.
Extended Data Figure 6 |. Off-target analysis of human CD34 + HSPCs edited by SpCas9 RNP targeting BCL11A enhancer.From the PDF
Extended Data Figure 7 |. Editing of BCL11A enhancer in SCD patient ( β S β S ) HSPCs. NBSGW mice were transplanted with 3xNLS-Cas9 RNP with MS-sgRNA-1617 edited β S β S #1 CD34 + HSPCs 24 h (day 1) or 48 h (day 2) after electroporation. BM were collected 16 weeks after transplantation and analyzed by flow cytometry for human cell chimerism (a) , multilineage reconstitution (b) or human erythroid cells (c) in BM, as well as the indel frequencies determined by TIDE analysis (d) . Error bars indicate standard deviation. e , Editing efficiency of 3xNLS-Cas9 coupled with MS-sgRNA-AAVS1 for control and -1617 for BCL11A enhancer editing in β S β S #2 CD34 + HSPCs as measured by TIDE analysis. f , β -like globin expression by RT-qPCR analysis in erythroid cells in vitro differentiated from RNP edited β S β S #2 CD34 + HSPCs. Error bars indicate standard deviation (n = 3 replicates). g , Multilineage reconstitution analysis of BM collected from mice engrafted with control or edited CD34 + HSPCs (from donor β S β S #2 ). h , Analysis of in vitro sickling of unedited control or edited enucleated β S β S #2 erythroid cells. Images were taken every 1 minute after MBS treatment. Result shown as percent sickled cells at each time point. Data are plotted as mean ± SD for (b, e, f, g) . Median of each group with 1 to 3 mice is shown as line for the other panels.
Extended Data Figure 7 |. Editing of BCL11A enhancer in SCD patient ( β S β S ) HSPCs. NBSGW mice were transplanted with 3xNLS-Cas9 RNP with MS-sgRNA-1617 edited β S β S #1 CD34 + HSPCs 24 h (day 1) or 48 h (day 2) after electroporation. BM were collected 16 weeks after transplantation and analyzed by flow cytometry for human cell chimerism (a) , multilineage reconstitution (b) or human erythroid cells (c) in BM, as well as the indel frequencies determined by TIDE analysis (d) . Error bars indicate standard deviation. e , Editing efficiency of 3xNLS-Cas9 coupled with MS-sgRNA-AAVS1 for control and -1617 for BCL11A enhancer editing in β S β S #2 CD34 + HSPCs as measured by TIDE analysis. f , β -like globin expression by RT-qPCR analysis in erythroid cells in vitro differentiated from RNP edited β S β S #2 CD34 + HSPCs. Error bars indicate standard deviation (n = 3 replicates). g , Multilineage reconstitution analysis of BM collected from mice engrafted with control or edited CD34 + HSPCs (from donor β S β S #2 ). h , Analysis of in vitro sickling of unedited control or edited enucleated β S β S #2 erythroid cells. Images were taken every 1 minute after MBS treatment. Result shown as percent sickled cells at each time point. Data are plotted as mean ± SD for (b, e, f, g) . Median of each group with 1 to 3 mice is shown as line for the other panels.From the PDF
Image 8
From the PDF
Image 9
From the PDF
Extended Data Figure 10 |. Flow cytometry of CD34 + HSPCs with 24 hours of culture. Cryopreserved G-CSF mobilized CD34 + HSPCs were stained with CD34, CD38, CD90, and CD45RA antibodies (in a ), or stained with Hoechst 33342 and Pyronin Y (in b ) at 0 hours following thaw or after 24 hours in culture with SCF, TPO and FLT3-L. HSPCs were electroporated with RNP with 3x-NLS-SpCas9 with BCL11A enhancer or AAVS1 targeting sgRNA. After 2 hour recovery, cells were stained with CD34, CD38, CD90, and CD45RA or with Hoechst 33342 and Pyronin Y, and sorted according to gates as shown in c -d .
Extended Data Figure 10 |. Flow cytometry of CD34 + HSPCs with 24 hours of culture. Cryopreserved G-CSF mobilized CD34 + HSPCs were stained with CD34, CD38, CD90, and CD45RA antibodies (in a ), or stained with Hoechst 33342 and Pyronin Y (in b ) at 0 hours following thaw or after 24 hours in culture with SCF, TPO and FLT3-L. HSPCs were electroporated with RNP with 3x-NLS-SpCas9 with BCL11A enhancer or AAVS1 targeting sgRNA. After 2 hour recovery, cells were stained with CD34, CD38, CD90, and CD45RA or with Hoechst 33342 and Pyronin Y, and sorted according to gates as shown in c -d .From the PDF
Figure 1 Identification of efficient BCL11A enhancer guide RNAs for HbF induction and amelioration of β -thalassemia.
Figure 1 Identification of efficient BCL11A enhancer guide RNAs for HbF induction and amelioration of β -thalassemia.From the PDF
Figure 2 Highly efficient BCL11A enhancer editing in HSCs.
Figure 2 Highly efficient BCL11A enhancer editing in HSCs.From the PDF
Figure 3 Editing BCL11A enhancer in SCD patient HSCs prevents sickling.
Figure 3 Editing BCL11A enhancer in SCD patient HSCs prevents sickling.From the PDF
Figure 4 Persistence of NHEJ repaired alleles in HSCs.
Figure 4 Persistence of NHEJ repaired alleles in HSCs.From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Lin, S., Staahl, B., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 3, 1–13 (2014).

Cited by

See all 551

Metadata

Authors
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., Shen, A. H., Ren, C., Esrick, E. B., Manis, J. P., Dorfman, D. M., Williams, D. A., Biffi, A., Brugnara, C., Biasco, L., Brendel, C., Pinello, L., Tsai, S. Q., Wolfe, S. A., & Bauer, D. E.
Affiliations
  • Broad Institute (US)
  • University of Massachusetts Chan Medical School (US)
  • Brigham and Women's Hospital (US)
  • St. Jude Children's Research Hospital (US)
Corresponding author
Bauer, Daniel E.
Venue
Nature Medicine
Published
2019-03-25
Volume
25
Issue
5
Pages
776-783
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2923636118
Cited by
515
References
48
Citations by year
2026: 33 · 2025: 71 · 2024: 61 · 2023: 74 · 2022: 74 · 2021: 85 · 2020: 84 · 2019: 33
FWCI
38.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • Doris Duke Charitable Foundation (2013137, 2015134)
  • Kenneth Rainin Foundation (KRA000003)
  • National Institutes of Health (UL1TR001102)
  • National Heart, Lung, and Blood Institute (P01HL053749, DP2HL137300, R01HL137848, P01HL032262, R21HL145636, U01HL117720)
  • National Human Genome Research Institute (R00HG008399)
  • National Institute of General Medical Sciences (R01GM115911)
  • National Institute of Allergy and Infectious Diseases (R01AI117839)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R03DK109232, K08DK093705, U54DK106829)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
sickle cell disease, beta-thalassemia, fetal hemoglobin induction, hematopoietic stem cells, CRISPR/Cas9, ribonucleoprotein delivery, non-homologous end joining, microhomology-mediated end joining, genome editing efficiency, genotoxicity
MeSH terms
Gene Editing, RNA, Guide, CRISPR-Cas Systems, Amino Acid Sequence, Anemia, Sickle Cell, Base Sequence, Carrier Proteins, Enhancer Elements, Genetic, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Nuclear Proteins, Repressor Proteins, Erythroid Precursor Cells, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, INDEL Mutation, gamma-Globins, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly efficient therapeutic gene editing of human hematopoietic stem cells. https://app.cochat.ai/papers/10.1038/s41591-019-0401-y
The paper
Wu, Y., Zeng, J., Roscoe, B. P., Liu, P., Yao, Q., Lazzarotto, C. R., Clement, K., Cole, M. A., Luk, K., Baricordi, C., Shen, A. H., Ren, C., Esrick, E. B., Manis, J. P., Dorfman, D. M., Williams, D. A., Biffi, A., Brugnara, C., Biasco, L., . . . Bauer, D. E. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine. https://doi.org/10.1038/s41591-019-0401-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.